Short answer
Liquidia Corp (LQDA) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $225M (up 314.6% year over year) with net income of −$236M.
Q3 2026 key financials · XBRL
- Revenue
- $225M
- +314.6% YoY · +31.2% QoQ
- Net income
- −$236M
- −6589.2% YoY · −416.3% QoQ
- Operating margin
- -117.0%
- EPS (diluted)
- −$2.48
- −8166.7% YoY · −435.1% QoQ
Source: XBRL data from the Liquidia Corp (LQDA) Q3 2026 10-Q on SEC EDGAR. USD.
Liquidia Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $225.3M, up $171.0M from $54.3M YoY, driven by YUTREPIA product sales
- Product sales $222.7M vs $51.7M YoY, strongest line; service revenue $2.6M vs $2.7M
- Operating loss $263.5M vs $1.8M income, including $389.7M litigation settlement charge
- Cash provided by operations $279.9M vs $79.9M used YoY; investing use $32.0M, financing use $42.5M
- PH-ILD label removal and promotion cessation, $105.4M cash restricted for UTC payments, further $145.4M payable by April 2027
Risk Factors
- New trade-policy risk: April 2026 executive order sought 100% tariffs on imported branded or patented pharmaceuticals without U.S. manufacturing
- Regulatory risk: Settlement Agreement removed PH-ILD from YUTREPIA’s label, narrowing its commercial opportunity versus Tyvaso
- Competitive risk: Generic Tyvaso entered the market effective January 1, 2026
- Financial risk: HCR facility requires minimum cash and cash equivalents of $45.0 million
- Compliance risk: August 2026 SEC-FDA information-sharing agreement increased insider-trading enforcement exposure for FDA-related information
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Liquidia Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.